Last reviewed · How we verify
Amlodipine + Simvastatin
Amlodipine + Simvastatin is a Calcium channel blocker + HMG-CoA reductase inhibitor (statin) Small molecule drug developed by University of Pavia. It is currently FDA-approved for Hypertension with hypercholesterolemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
This combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (amlodipine) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin).
This combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (amlodipine) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin). Used for Hypertension with hypercholesterolemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.
At a glance
| Generic name | Amlodipine + Simvastatin |
|---|---|
| Sponsor | University of Pavia |
| Drug class | Calcium channel blocker + HMG-CoA reductase inhibitor (statin) |
| Target | L-type voltage-gated calcium channel; HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral resistance. Simvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. Together, they address two major cardiovascular risk factors.
Approved indications
- Hypertension with hypercholesterolemia
- Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Common side effects
- Headache
- Peripheral edema
- Flushing
- Muscle pain/myalgia
- Elevated liver enzymes
- Dizziness
Key clinical trials
- Statin Combined with Amlodipine Treats Primary Aldosteronism (PHASE4)
- Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults
- Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes (PHASE3)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Nephropathy In Type 2 Diabetes and Cardio-renal Events (PHASE4)
- Gut Microbiomes in Patients With Metabolic Syndrome
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine + Simvastatin CI brief — competitive landscape report
- Amlodipine + Simvastatin updates RSS · CI watch RSS
- University of Pavia portfolio CI
Frequently asked questions about Amlodipine + Simvastatin
What is Amlodipine + Simvastatin?
How does Amlodipine + Simvastatin work?
What is Amlodipine + Simvastatin used for?
Who makes Amlodipine + Simvastatin?
What drug class is Amlodipine + Simvastatin in?
What development phase is Amlodipine + Simvastatin in?
What are the side effects of Amlodipine + Simvastatin?
What does Amlodipine + Simvastatin target?
Related
- Drug class: All Calcium channel blocker + HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting L-type voltage-gated calcium channel; HMG-CoA reductase
- Manufacturer: University of Pavia — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension with hypercholesterolemia
- Indication: Drugs for Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing